PEGylated drugs in rheumatology--why develop them and do they work? - Wikidata - wikimedia - TriplyDB

PEGylated drugs in rheumatology--why develop them and do they work?

PEGylated drugs in rheumatology--why develop them and do they work?

http://www.wikidata.org/entity/Q38130374

about

Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Harnessing nanoparticles for immune modulation Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome

P2860

Q30300201-FB1E0E03-9BD7-42EE-B360-590CDB313C81 Q33766720-FB05969D-6811-4EB3-B73F-F6F38C5E819A Q35236103-4441EFC5-45D4-4E50-B6EE-575010B9A8E5 Q35252156-CF0F5E19-B5A1-4041-A87E-2DA123678CD6 Q36154772-6BB3DE0F-947C-4518-B674-EC244C2DBF20 Q37670073-BBA7F03B-298E-4EF9-A120-9FBB4D73658C Q38208275-7B5BA69E-C902-47D5-BB31-CADAAC73DD56 Q39646028-F8334332-3EDE-4EC0-9014-B09F82A2B197 Q57330038-F185245E-7C42-4A1C-B033-014CD126E8E2 Q58580417-4973EB5C-2134-4E27-AF73-41878782C708

P2860

PEGylated drugs in rheumatology--why develop them and do they work?

http://www.wikidata.org/entity/Q38130374

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

PEGylated drugs in rheumatology--why develop them and do they work?

@en

type

label

PEGylated drugs in rheumatology--why develop them and do they work?

@en

prefLabel

PEGylated drugs in rheumatology--why develop them and do they work?

@en

P1433

Q38130374-4DEC3D2E-266F-4841-8B70-275044F2AA62

P1476

Q38130374-C05CC6FF-05F6-42DC-B009-3ECA3C2C28A8

P2093

Q38130374-2AB242D9-29B2-4C66-B35F-8D791694D445

Q38130374-EE5D56C2-46C6-4261-B642-4FBF40055815

Q38130374-F1D35D74-E6DF-42E5-9558-E643680DE58D

P275

Q38130374-D94DF8DC-3B54-4A96-AAF8-8CFD5D8FEA2C

P2860

Q38130374-029C3896-0BB8-482E-93F2-434215FBEBC2

Q38130374-116BAFC5-A8ED-476D-9276-500FC40D4E50

Q38130374-12D0E2D8-D813-461F-B7E3-77F09E535311

Q38130374-21BA160A-7B33-4828-AAE0-A12C2558CD46

Q38130374-33FC1B15-4AC1-42F6-A83F-594CF05A6C2B

Q38130374-3A068243-D735-429E-9B3B-865D27D8FE26

Q38130374-3CE00806-132A-4CF9-A216-1E48164E1DD9

Q38130374-4106F02E-BD2A-49A3-9210-63208FBA3E55

Q38130374-4BA382D4-9EBD-4F92-B6F2-786B5F45C1FB

Q38130374-5223B0C9-12BF-4FFB-8BD4-990C7E2A6C5D

P304

Q38130374-314E8419-4C05-49CE-8441-666D6B8DFD06

P31

Q38130374-24F6AEC9-F1AA-48C5-BA24-44B59F63B360

Q38130374-2A48EDF5-7F1C-404D-91AD-BB77596FE1F3

P356

Q38130374-1A77C684-A698-4FEB-9D20-AB04CE3378A0

P433

Q38130374-0F842A99-7CD5-41A8-9408-7E688483A1DD

P478

Q38130374-616F3EDA-4E9B-4CD1-9FB5-1BE03865D45B

P577

Q38130374-979C45FA-E7E7-44E2-9287-9FBCD9059E37

Q38130374-AE843DD2-DA22-4C6C-9E7B-53A87DEB31A4

P5875

Q38130374-BF9FC1DD-1446-4E2C-96E9-BE88EAA64621

P698

Q38130374-40C0863A-A2B2-41D9-8807-14E2DDB3F396

P921

Q38130374-0F8C80D4-992E-423D-B583-B10CBE84DA0B

Q38130374-571B99F2-A373-4965-B8D5-AD417D15C29F

Q38130374-5AB86248-AED0-41A7-BEBE-41F8E8B3A367

P932

Q38130374-DE0BD3F9-7D03-42A4-9AE5-AAFC43DC012F

P356

P1433

P1476

PEGylated drugs in rheumatology--why develop them and do they work?

@en

P2093

Anisur Rahman

http://www.w3.org/2001/XMLSchema#string

Thomas McDonnell

http://www.w3.org/2001/XMLSchema#string

Yiannis Ioannou

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Biologic agents in rheumatoid arthritis: an update for managed care professionals

Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus

A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization.

Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.

Structural and biologic characterization of pegylated recombinant IFN-alpha2b.

Emerging PEGylated drugs.

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.

P304

391-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KET278

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256073797

http://www.w3.org/2001/XMLSchema#string

P698

23962623

http://www.w3.org/2001/XMLSchema#string

P921

manufactured product

macromolecular substances

P932

3930883

http://www.w3.org/2001/XMLSchema#string